Michael Kershaw

Michael received a PhD from the University of Melbourne in 1997 for his studies into the genetic redirection of immunity against cancer. He performed Postdoctoral studies in cancer immunotherapy in the laboratories of Dr Steven Rosenberg at the National Cancer Institute in Bethesda, Maryland from 1998 to 2001. He returned to Australia in 2002 and took up a position in the Cancer Immunology Program at Peter Mac. Michael’s laboratory is involved in the development of effective immunotherapies for cancer. The approaches involve novel in-house derived strategies and new ways of using existing immunomodulatory reagents. Using these approaches in mouse tumour models, he seeks to determine the cellular and molecular mechanisms of immune-mediated anti-tumour effects. The principal research interests of the lab lie in understanding the tumour microenvironment and in the use of adoptive immunotherapy and vaccines for cancer treatment. Michael is a key inventor of the Currus Biologics technology and has previously developed a CAR-T that is currently in clinical development and licensed to Bristol Myers Squib.